Oric Pharmaceuticals (ORIC) Share-based Compensation (2019 - 2026)
Oric Pharmaceuticals (ORIC) posted Share-based Compensation of $6.9 million for Q1 2026, up 9.88% on a QoQ basis from $6.3 million in Q4 2025, and up 5.25% year-over-year from $6.6 million in Q1 2025.
Oric Pharmaceuticals (ORIC) Share-based Compensation (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- Quarterly Share-based Compensation rose 5.25% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (up 16.38% YoY) and the FY2025 annual result came in at $25.0 million, down 20.77% from the prior year.
- Share-based Compensation was $6.9 million for Q1 2026 at Oric Pharmaceuticals, up from $6.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.9 million in Q1 2026 and bottomed at $3.1 million in Q4 2022.
- A 5-year average of $4.8 million and a median of $5.0 million in 2024 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 43.77% in 2022, while the deepest fall reached 10.55% in 2022.
- Oric Pharmaceuticals' Share-based Compensation stood at $3.1 million in 2022, then advanced by 25.34% to $3.9 million in 2023, then surged by 32.63% to $5.2 million in 2024, then increased by 20.66% to $6.3 million in 2025, then rose by 9.88% to $6.9 million in 2026.
- Business Quant data shows ORIC's Share-based Compensation at $6.9 million in Q1 2026, $6.3 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Oric Pharmaceuticals | 1.15 Bn | 866.67 Mn | - | 6.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.90 Mn |
| Mar 31, 2026 | 6.90 Mn |
| Dec 31, 2025 | 6.28 Mn |
| Dec 31, 2025 | 6.28 Mn |
| Sep 30, 2025 | 5.63 Mn |
| Sep 30, 2025 | 5.63 Mn |
| Jun 30, 2025 | 6.57 Mn |
| Jun 30, 2025 | 6.57 Mn |
| Mar 31, 2025 | 6.55 Mn |
| Mar 31, 2025 | 6.55 Mn |
| Dec 31, 2024 | 5.20 Mn |
| Dec 31, 2024 | 5.20 Mn |
| Sep 30, 2024 | 5.06 Mn |
| Sep 30, 2024 | 5.06 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Mar 31, 2024 | 4.96 Mn |
| Mar 31, 2024 | 4.96 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Dec 31, 2023 | 3.92 Mn |